ONC and ONYN Related Headlines
Go Back- Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
- Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
- Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
- Oncolytics plans FDA talks for pancreatic cancer drug trial
- Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
- Oncolytics Biotech regains compliance with NASDAQ minimum bid price rule
- Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
- Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
- Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
ONC and ONYN Related Press Releases
Go Back- Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study
- Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
- Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
- Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
- Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
- Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy
- Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
